Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management-Reference-Cited by-同舟云学术

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

Published:2023-08-18 Issue:1 Volume:51 Page:295-303
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Pathmanathan Shivanshan,Tariq Arsalan,Pearce Adam,Rhee Handoo,Kyle Samuel,Raveenthiran Sheliyan,Wong David,McBean Rhiannon,Marsh Phillip,Goodman Steven,Dhiantravan Nattakorn,Esler Rachel,Dunglison Nigel,Navaratnam Anojan,Yaxley John,Thomas Paul,Pattison David A.,Goh Jeffrey C.,Gan Chun Loo,Roberts Matthew J.^ORCID

Abstract

Abstract Purpose There is an emerging role of the use of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in renal cell carcinoma. Herein, we report our experience in use of PSMA PET in recurrent or metastatic renal cell carcinoma (RCC). Methods A retrospective analysis of all patients who underwent PSMA PET for suspected recurrent or de-novo metastatic RCC between 2015 and 2020 at three institutions was performed. The primary outcome was change in management (intensification or de-intensification) following PSMA PET scan. Secondary outcomes included histopathological correlation of PSMA avid sites, comparison of sites of disease on PSMA PET to diagnostic CT and time to systemic treatment. Results

Funder

The University of Queensland

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-023-06380-4.pdf

Reference20 articles.

1. Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11:79–87. https://doi.org/10.14740/wjon1279.

2. Ahn T, Roberts MJ, Abduljabar A, Joshi A, Perera M, Rhee H, et al. A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC). Mol Imaging Biol. 2019;21:799–807. https://doi.org/10.1007/s11307-018-01307-0.

3. Tyson MD, Chang SS. Optimal Surveillance Strategies After Surgery for Renal Cell Carcinoma. J Natl Compr Canc Netw. 2017;15:835–40. https://doi.org/10.6004/jnccn.2017.0102.

4. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16:2261–6. https://doi.org/10.1200/JCO.1998.16.6.2261.

5. Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021;22:1732–9. https://doi.org/10.1016/S1470-2045(21)00528-3.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort;European Urology Focus;2024-01

2. High Prognostic Value of 68Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry;Diagnostics;2023-09-28